MX2010003556A - Regimen de tratamiento para trastornos proliferantes. - Google Patents

Regimen de tratamiento para trastornos proliferantes.

Info

Publication number
MX2010003556A
MX2010003556A MX2010003556A MX2010003556A MX2010003556A MX 2010003556 A MX2010003556 A MX 2010003556A MX 2010003556 A MX2010003556 A MX 2010003556A MX 2010003556 A MX2010003556 A MX 2010003556A MX 2010003556 A MX2010003556 A MX 2010003556A
Authority
MX
Mexico
Prior art keywords
subject
administering
proliferative disorders
treatment regime
reovirus
Prior art date
Application number
MX2010003556A
Other languages
English (en)
Inventor
Matthew C Coffey
Bradley G Thompson
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Publication of MX2010003556A publication Critical patent/MX2010003556A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proveen m?todos aqu? para el tratamiento o mejoramiento de un trastorno proliferante en un sujeto. El m?todo contiene las etapas de administrar al sujeto una dosis de un agente inmunosupresor seguido por la administraci?n al sujeto de una a cinco dosis de un reovirus. El agente inmunosupresor se administra al sujeto al menos aproximadamente 72 horas antes de la administraci?n del reovirus. Tambi?n se proveen aqu? m?todos para el tratamiento o mejoramiento de un trastorno proliferante en un sujeto incluyendo las etapas de administrar al sujeto un virus oncol?tico y un agente de modulaci?n de c?lula B. Tambi?n se proveen kits y composiciones farmac?uticas que contienen un virus oncol?tico y al menos un agente de modulaci?n de c?lulas B.
MX2010003556A 2007-10-22 2008-10-22 Regimen de tratamiento para trastornos proliferantes. MX2010003556A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98171607P 2007-10-22 2007-10-22
PCT/CA2008/001865 WO2009052617A1 (en) 2007-10-22 2008-10-22 Treatment regime for proliferative disorders

Publications (1)

Publication Number Publication Date
MX2010003556A true MX2010003556A (es) 2010-04-21

Family

ID=40579002

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003556A MX2010003556A (es) 2007-10-22 2008-10-22 Regimen de tratamiento para trastornos proliferantes.

Country Status (9)

Country Link
US (1) US20100247622A1 (es)
EP (1) EP2211880A4 (es)
JP (1) JP2011500608A (es)
CN (1) CN101820892A (es)
AU (1) AU2008316276A1 (es)
CA (1) CA2699805A1 (es)
MX (1) MX2010003556A (es)
WO (1) WO2009052617A1 (es)
ZA (1) ZA201002167B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009135614A2 (en) * 2008-05-09 2009-11-12 Bayer Schering Pharma Aktiengesellschaft Use of a virus regimen for the treatment of diseases
CN102695520A (zh) * 2008-05-27 2012-09-26 昂科利蒂克斯生物科技公司 调节间隙压力与溶瘤病毒的递送和分布
TW200950777A (en) * 2008-05-27 2009-12-16 Oncolytics Biotech Inc Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
DE102013105144A1 (de) * 2013-05-17 2014-11-20 Arno Thaller Pharmazeutisches Kombinationspräparat mit einem anti-idiotypischen Antikörperfragment
CN106489075B (zh) * 2014-07-11 2019-10-15 爱科谱迅病理研究公司 针对GTP酶KRas蛋白质(KRas)的SRM/MRM测定
BR112017018160A2 (pt) 2015-02-25 2018-04-10 Memorial Sloan-Kettering Cancer Center uso do vírus vaccinia ankara modificado (mva) não replicante inativado como monoimunoterpia ou em combinação com agentes de bloqueio de pontos de verificação imunológica para tumores sólidos
CN107847534B (zh) 2015-04-17 2022-10-04 纪念斯隆凯特琳癌症中心 Mva或mvaδe3l作为抗实体瘤的免疫治疗剂的应用
EP3419648A4 (en) 2016-02-25 2019-09-11 Memorial Sloan-Kettering Cancer Center ATTENUATED REPLICATION-VACCINE VIRUSES WITH THYMIDINE KINASE DELETION WITH AND WITHOUT EXPRESSION OF FLT3L OR HUMAN GM-CSF FOR ANTICANCER IMMUNOTHERAPY
KR20180130500A (ko) 2016-02-25 2018-12-07 메모리얼 슬로안 케터링 캔서 센터 인간 flt3l을 발현하는 재조합 mva 또는 mvaδe3l 및 고형 종양에 대한 면역요법제로서 그의 용도
CN106177955B (zh) * 2016-08-18 2018-03-16 广州威溶特医药科技有限公司 Bcl‑xL抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用
CN108606982B (zh) 2016-08-18 2020-02-04 广州威溶特医药科技有限公司 Vcp抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用
CN106265764B (zh) * 2016-08-18 2018-03-16 广州威溶特医药科技有限公司 Iap抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用
US11242509B2 (en) 2017-05-12 2022-02-08 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
US20220111034A1 (en) * 2019-01-18 2022-04-14 Université Catholique de Louvain Virus compositions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
US6565831B1 (en) * 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
CN1281336A (zh) * 1997-10-09 2001-01-24 病毒防御公司 使用病毒来治疗赘生物
TWI289158B (en) * 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
CA2428206C (en) * 2000-11-09 2005-09-27 Oncolytics Biotech Inc. Methods for the treatment of cellular proliferative disorders
AR035227A1 (es) * 2001-02-20 2004-05-05 Oncolytics Biotech Inc Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
WO2002074940A1 (en) * 2001-03-16 2002-09-26 Oncolytics Biotech, Inc. Method of extracting virus from cell culture
US7163678B2 (en) * 2002-11-07 2007-01-16 Oncolytics Biotech Inc. Reovirus for the treatment of ral-mediated cellular proliferative disorders
WO2005002607A2 (en) * 2003-07-07 2005-01-13 Oncolytics Biotech Inc. Oncolytic reoviruses for the treatment of neoplasms having activated pp2a or rac
WO2007093036A1 (en) * 2006-02-13 2007-08-23 Oncolytics Biotech Inc. Use of local immune suppression to enhance oncolytic viral therapy
CA2678721C (en) * 2007-03-12 2018-02-13 Oncolytics Biotech Inc. Reoviruses having modified sequences
AR066649A1 (es) * 2007-05-21 2009-09-02 Oncolytics Biotech Inc Reovirus mutantes y metodos de elaboracion y uso de los mismos

Also Published As

Publication number Publication date
AU2008316276A1 (en) 2009-04-30
ZA201002167B (en) 2011-06-29
WO2009052617A1 (en) 2009-04-30
CA2699805A1 (en) 2009-04-30
US20100247622A1 (en) 2010-09-30
AU2008316276A2 (en) 2010-05-13
WO2009052617A9 (en) 2010-08-05
EP2211880A4 (en) 2012-11-14
JP2011500608A (ja) 2011-01-06
CN101820892A (zh) 2010-09-01
EP2211880A1 (en) 2010-08-04

Similar Documents

Publication Publication Date Title
MX2010003556A (es) Regimen de tratamiento para trastornos proliferantes.
NZ602675A (en) Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
WO2013078440A3 (en) Enhanced treatment regimens using mtor inhibitors
RU2017134443A (ru) Способ лечения с применением традипитанта
RU2013148721A (ru) Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения
MX344476B (es) Metodos de tratar trastornos pulmonares con formulaciones de amikacina liposomal.
MX2009008582A (es) Metodo para la administracion terapeutica de dihidroergotamina para permitir un rapido alivio de la migraña mientras se minimiza el perfil de efectos secundarios.
CO6251212A2 (es) Tratamiento terapeutico de sindrome metabolico diabetes tipo 2 obesidad o prediabetes
MX2014013039A (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple.
JP2018090566A5 (es)
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
WO2014198852A3 (en) A dosing regime and formulations for type b adenoviruses
AU2019205327A8 (en) Intranasal delivery of levodopa powder by precision olfactory device
RU2008105603A (ru) Лечение рака с применением вирусов, фторпиримидинов и камптотецинов
JP2016505050A5 (es)
BR112012020185A2 (pt) uso de preparações de heparina oral para tratar doenças e afecções do trato urinário.
NO20075945L (no) Behandling, prevensjon og ameliorasjon av lungelidelser assosiert med kjemoterapi eller radioterapi med aktive vitamin D sammensetninger eller imitatorer derav
MX2013003523A (es) Composicion farmaceutica de dosis baja.
BR112020013750A8 (pt) Dispensação intranasal de olanzapina por dispositivo olfativo de precisão
MY193963A (en) Composition for treating joint diseases and kit containing same
MX2010006724A (es) Regimenes terapeuticos para el tratamiento de desordenes inmunoinflamatorios.
MX2012005497A (es) Tivozanib y temsirolimus en combinacion.
MX2010006310A (es) O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor.
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal